AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9638033 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4.5 mg caffeine/kg fat-free mass)
Number of subjects: 16
Study 9638033 — intervention group
Group type: COMPARATOR
Intervention: Control (no caffeine)
Number of subjects: 16
Study 8206809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 150 mg
Number of subjects: 18
Study 8206809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 300 mg
Number of subjects: 18
Study 8206809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 18
Study 8206809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2536517 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil
Number of subjects: 32
Study 2536517 — intervention group
Group type: COMPARATOR
Intervention: Olive-oil
Number of subjects: 32
Study 4885615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (400 mg daily for 14 months, then 800 mg daily for 11 months)
Number of subjects: 169
Study 4885615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 31996130 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (performed masseter muscle massage and stretching of jaw and neck joints before anesthetic induction)
Number of subjects: 138
Study 31996130 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 138
Study 31996130 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 138
Study 30365461 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted corticosteroid delivery (topical triamcinolone acetonide 20 mg/mL)
Number of subjects: 20
Study 30365461 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted 5-fluorouracil delivery (topical 5-fluorouracil 50 mg/mL)
Number of subjects: 20
Study 26269215 — intervention group
Group type: EXPERIMENTAL
Intervention: T-tube (TT)
Number of subjects: 21
Study 26269215 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 21
Study 25304269 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian drilling (LOD)
Number of subjects: 110
Study 25304269 — intervention group
Group type: COMPARATOR
Intervention: Metformin (Met)
Number of subjects: 110
Study 24131091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinpoint irradiation technique by CO₂ LASER (14 patients)
Number of subjects: 32
Study 24131091 — intervention group
Group type: COMPARATOR
Intervention: TCA CROSS (14 patients)
Number of subjects: 32
Study 23244536 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/d c9, t11 CLA for 16 weeks
Number of subjects: 31
Study 23244536 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g/d c9, t11 CLA for 16 weeks
Number of subjects: 31
Study 23244536 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 31
Study 19032576 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 0.5 mg/d
Number of subjects: 15
Study 19032576 — intervention group
Group type: COMPARATOR
Intervention: sertraline 200 mg/d
Number of subjects: 15
Study 17522585 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) 70 microg/kg administered intravenously
Number of subjects: 23
Study 17522585 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa)
Number of subjects: 23
Study 17522585 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 23
Study 15866013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium Virugard (95% ethanol)
Number of subjects: 0
Study 15866013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium Rub (80% ethanol)
Number of subjects: 0
Study 15866013 — intervention group
Group type: EXPERIMENTAL
Intervention: Desderman N (75.1% ethanol)
Number of subjects: 0
Study 15866013 — intervention group
Group type: COMPARATOR
Intervention: 70% ethanol
Number of subjects: 0
Study 15866013 — intervention group
Group type: COMPARATOR
Intervention: 70% propan-1-ol
Number of subjects: 0
Study 12528763 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve weeks of treadmill exercise training
Number of subjects: 32
Study 12528763 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 32
Study 9606434 — intervention group
Group type: EXPERIMENTAL
Intervention: Paranoid schizophrenia
Number of subjects: 84
Study 9606434 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual schizophrenia
Number of subjects: 84
Study 9606434 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorganized schizophrenia
Number of subjects: 84
Study 9606434 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 84
Study 7705381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-plasminogen activator
Number of subjects: 0
Study 7705381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2649461 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical infusion of metronidazole solution
Number of subjects: 0
Study 2649461 — intervention group
Group type: COMPARATOR
Intervention: Treatment without metronidazole
Number of subjects: 0
Study 360759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 8-4650
Number of subjects: 37
Study 360759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31952545 — intervention group
Group type: EXPERIMENTAL
Intervention: VIDE induction and VAI/VAC/BuMel consolidation
Number of subjects: 0
Study 31952545 — intervention group
Group type: EXPERIMENTAL
Intervention: VDC/IE induction and IE/VC/VAI/BuMel consolidation
Number of subjects: 0
Study 31952545 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of zoledronic acid to consolidation chemotherapy
Number of subjects: 0
Study 28322667 — intervention group
Group type: EXPERIMENTAL
Intervention: PATH Program (8-week intervention)
Number of subjects: 20
Study 28322667 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group (revised version of the program)
Number of subjects: 20
Study 26925641 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care training package (seven group training sessions)
Number of subjects: 42
Study 26925641 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 24559811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 24559811 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g of ginger
Number of subjects: 45
Study 24559811 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g of ginger
Number of subjects: 45
Study 22517413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine with lopinavir/ritonavir
Number of subjects: 0
Study 22517413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine with darunavir/ritonavir
Number of subjects: 0
Study 22517413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine with atazanavir/ritonavir
Number of subjects: 0
Study 22517413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine with atazanavir (without ritonavir)
Number of subjects: 0
Study 22517413 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir with/without ritonavir
Number of subjects: 0
Study 20439056 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (average 10 sessions)
Number of subjects: 9990
Study 20439056 — intervention group
Group type: EXPERIMENTAL
Intervention: Internists
Number of subjects: 9990
Study 20439056 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedists
Number of subjects: 9990
Study 20439056 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 9990
Study 18605178 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent movie previews
Number of subjects: 159
Study 18605178 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent movie previews
Number of subjects: 159
Study 15824361 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 1,300 mg/day
Number of subjects: 30
Study 15824361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12066083 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous stitch closure
Number of subjects: 964
Study 12066083 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous drain placement
Number of subjects: 964
Study 12066083 — intervention group
Group type: COMPARATOR
Intervention: No closure
Number of subjects: 964
Study 10910540 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular insulin (RI) infusion (n = 20); ratio of infusion glucose to regular insulin was 10‐15 gm glucose to 1 unit RI, glucose infusion rate maintained at least 6 mg/Kg/min.
Number of subjects: 40
Study 10910540 — intervention group
Group type: COMPARATOR
Intervention: Kayexalate resin enema (n = 20); dose of Kayexalate was 1 gm/Kg body weight given rectally every four hours.
Number of subjects: 40
Study 8584194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural analgesia with bupivacaine boluses
Number of subjects: 0
Study 8584194 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural analgesia with bupivacaine and morphine
Number of subjects: 0
Study 8584194 — intervention group
Group type: COMPARATOR
Intervention: Endovenous analgesia with morphine boluses
Number of subjects: 0
Study 1773242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Management (NM)
Number of subjects: 55
Study 1773242 — intervention group
Group type: COMPARATOR
Intervention: Stress Management (SM)
Number of subjects: 55
Study 6295422 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential hemi-body irradiation (HBI)
Number of subjects: 64
Study 6295422 — intervention group
Group type: COMPARATOR
Intervention: 3-drug cyclic chemotherapy (CC)
Number of subjects: 64
Study 31272528 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg memantine tablet formulation A
Number of subjects: 19
Study 31272528 — intervention group
Group type: COMPARATOR
Intervention: 10 mg memantine tablet formulation B
Number of subjects: 19
Study 29453468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4mg (Group 2)
Number of subjects: 120
Study 29453468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25mg/kg (Group 3)
Number of subjects: 120
Study 29453468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 0.5mg/kg (Group 4)
Number of subjects: 120
Study 29453468 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group 1)
Number of subjects: 120
Study 26066703 — intervention group
Group type: EXPERIMENTAL
Intervention: Siluron2000 silicone oil
Number of subjects: 72
Study 26066703 — intervention group
Group type: EXPERIMENTAL
Intervention: F4H5 (perfluorobutylpentane)
Number of subjects: 72
Study 26066703 — intervention group
Group type: COMPARATOR
Intervention: Siluron5000 silicone oil
Number of subjects: 72
Study 25058083 — intervention group
Group type: EXPERIMENTAL
Intervention: HSCT
Number of subjects: 156
Study 25058083 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 156
Study 22984401 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel HIV confirmatory testing algorithm
Number of subjects: 9385
Study 18547343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 30
Study 18547343 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 30
Study 18547343 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 30
Study 17575222 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation plus radiotherapy (STAD+RT)
Number of subjects: 502
Study 17575222 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation plus radiotherapy (LTAD+RT)
Number of subjects: 502
Study 17575222 — intervention group
Group type: EXPERIMENTAL
Intervention: Bcl-2
Number of subjects: 502
Study 17575222 — intervention group
Group type: EXPERIMENTAL
Intervention: Bax
Number of subjects: 502
Study 15189492 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin (mean dose 0.33 +/- 0.15; range 0.09-0.66 units/kg/d) administered twice daily
Number of subjects: 26
Study 15189492 — intervention group
Group type: COMPARATOR
Intervention: Matched observation group (natural history studies)
Number of subjects: 26
Study 11606504 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (Is-MN)
Number of subjects: 133
Study 11606504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 9608152 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal LD group (VIQ >= 95, PIQ at least 25 points lower than VIQ)
Number of subjects: 89
Study 9608152 — intervention group
Group type: COMPARATOR
Intervention: Verbal LD group (PIQ >= 95, VIQ at least 25 points lower than PIQ)
Number of subjects: 89
Study 8083823 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant medications (average of 7.1 drugs per month for AIDS patients)
Number of subjects: 2801
Study 8083823 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant medications (average of 3.1 drugs per month for ARC patients)
Number of subjects: 2801
Study 8083823 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant medications (average of 2.7 drugs per month for asymptomatic patients)
Number of subjects: 2801
Study 8083823 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir usage
Number of subjects: 2801
Study 8083823 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug classes used
Number of subjects: 2801
Study 8083823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription vs. over-the-counter drugs
Number of subjects: 2801
Study 8083823 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic subgroup analysis
Number of subjects: 2801
Study 8083823 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivirals and vitamins consumption
Number of subjects: 2801
Study 8083823 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics or antipyretics consumption
Number of subjects: 2801
Study 3060379 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 20
Study 3060379 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonists
Number of subjects: 20
Study 30875386 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial exposure to a prosocial donation decision
Number of subjects: 200
Study 30875386 — intervention group
Group type: EXPERIMENTAL
Intervention: Contribution-to-others beliefs
Number of subjects: 200
Study 30875386 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy and self-development well-being beliefs interaction
Number of subjects: 200
Study 30875386 — intervention group
Group type: COMPARATOR
Intervention: Control groups (totally self-focused and no first-exposure)
Number of subjects: 200
Study 28985268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (targeting SBP ≤ 120 mm Hg)
Number of subjects: 9361
Study 28985268 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (targeting SBP ≤ 140 mm Hg)
Number of subjects: 9361
Study 25527747 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural almonds (NAs)
Number of subjects: 17
Study 25527747 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted almonds (RAs)
Number of subjects: 17
Study 23706890 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week yoga intervention
Number of subjects: 27
Study 23706890 — intervention group
Group type: COMPARATOR
Intervention: Attention-control activity
Number of subjects: 27
Study 16982941 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary training group (exercise and respiratory training)
Number of subjects: 30
Study 16982941 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 14572944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (practitioners who read and discussed the feedback report)
Number of subjects: 0
Study 14572944 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 14572944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 10226959 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-training
Number of subjects: 43
Study 10226959 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapist-supervised rehabilitation
Number of subjects: 43
Study 8723308 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paroxetine
Number of subjects: 0
Study 1806624 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin (60‐90 mg/day)
Number of subjects: 317
Study 6308685 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 25 mg t.i.d. alone
Number of subjects: 8
Study 6308685 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 25 mg t.i.d. with hydrochlorothiazide (HCTZ) 50 mg/day
Number of subjects: 8
Study 6308685 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ENA) 5 or 10 mg/day
Number of subjects: 8
Study 6308685 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ENA) with hydrochlorothiazide (HCTZ)
Number of subjects: 8
Study 6308685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31988226 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a commercial weight management programme plus stop smoking support (treatment group)
Number of subjects: 76
Study 31988226 — intervention group
Group type: COMPARATOR
Intervention: Stop smoking support alone (control group)
Number of subjects: 76
Study 31121138 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling Foley catheter
Number of subjects: 150
Study 31121138 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐catheterization
Number of subjects: 150
Study 31121138 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as those who did not pass the voiding trial)
Number of subjects: 150
Study 28403408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (i.v.‐bolus injection of 1.5 mg kg ‐1 at induction of anaesthesia, followed by an infusion of 1.5 mg kg ‐1 h ‐1 until six h after arrival at the post‐anaesthesia care unit)
Number of subjects: 70
Study 28403408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volumes of saline)
Number of subjects: 70
Study 28403408 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 70
Study 28403408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25171056 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,6-DMB supplement (1.5 g daily)
Number of subjects: 8
Study 25171056 — intervention group
Group type: COMPARATOR
Intervention: No supplement (Control)
Number of subjects: 8
Study 23535096 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor (rhC1INH) 50-U/kg intravenous dose
Number of subjects: 62
Study 23535096 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor (rhC1INH) repeated treatment
Number of subjects: 62
Study 21908890 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 67
Study 21908890 — intervention group
Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting (CABG)
Number of subjects: 67
Study 21908890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCI and CABG
Number of subjects: 67
Study 18829443 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean hand acupuncture therapy (HAT), 10 sessions
Number of subjects: 0
Study 18829443 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand moxibustion therapy (HMT), 10 sessions
Number of subjects: 0
Study 18829443 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16505133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 to 1.5 mg risperidone per day
Number of subjects: 473
Study 16505133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study 14989395 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine, 180 mg once daily (10 PM)
Number of subjects: 20
Study 14989395 — intervention group
Group type: EXPERIMENTAL
Intervention: Butterbur, 50 mg twice daily (8 AM and 10 PM)
Number of subjects: 20
Study 14989395 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg once daily (10 PM)
Number of subjects: 20
Study 14989395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11381380 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis plus intra-articular injection of sodium hyaluronate (SH)
Number of subjects: 41
Study 11381380 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis alone
Number of subjects: 41
Study 9216117 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate 100 mg tid
Number of subjects: 12
Study 9216117 — intervention group
Group type: COMPARATOR
Intervention: gemfibrozil 600 mg bid
Number of subjects: 12
Study 8256386 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3 ppm NO2
Number of subjects: 14
Study 8256386 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 14
Study 3311548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg plus Codeine 60 mg
Number of subjects: 195
Study 3311548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg plus Codeine 30 mg
Number of subjects: 195
Study 3311548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg alone
Number of subjects: 195
Study 3311548 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg alone
Number of subjects: 195
Study 3311548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 28443698 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nutritional supplementation (MNS) 252 kcal/day daily up to 12 weeks postpartum and four breastfeeding education and support sessions
Number of subjects: 228
Study 28443698 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal nutritional supplementation (MNS)
Number of subjects: 228
Study 28443698 — intervention group
Group type: COMPARATOR
Intervention: Control (standards of care)
Number of subjects: 228
Study 28025374 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 50
Study 28025374 — intervention group
Group type: COMPARATOR
Intervention: 0.1% ropivacaine
Number of subjects: 50
Study 25652604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus 2 Gy total body irradiation (Flu-TBI arm; n=49)
Number of subjects: 94